Guanfacine for attention deficit and hyperactivity disorder in pediatrics: A systematic review and meta-analysis

European Neuropsychopharmacology

Volumn 24, Issue 10, 2014, Pages 1578-1590

  Ruggiero, Simona ^a   Clavenna, Antonio ^b   Reale, Laura ^b   Capuano, Annalisa ^a   Rossi, Francesco ^a   Bonati, Maurizio ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Attention deficit disorder with hyperactivity; Child; Guanfacine; Meta analysis; Systematic review

Indexed keywords

GUANFACINE; PLACEBO; PSYCHOTROPIC AGENT;

ABDOMINAL PAIN; ASTHMA; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CHILDHOOD DISEASE; CLAVICLE FRACTURE; CLINICAL GLOBAL IMPRESSION SCALE; COCHRANE LIBRARY; CONCUSSION; CONFIDENCE INTERVAL; CONSCIOUSNESS DISORDER; CONVULSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EMBASE; FAINTNESS; FATIGUE; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; HYPOTENSION; LEG FRACTURE; MEDLINE; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; OUTCOME ASSESSMENT; OVARY CYST; PELVIS FRACTURE; PNEUMOTHORAX; PSYCINFO; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SINUS ARRHYTHMIA; SINUS BRADYCARDIA; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; GUANFACINE; HUMANS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907989911     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.08.001     Document Type: Review

References (58)

1. American Academy of Pediatrics ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention Deficit/Hyperactivity Disorder in Children and adolescents. Pediatrics 2011, 128:1007-1022.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders:DSM-IV-TR 2010, American Psychiatric Association, Washington D.C., (Task force on DSM-IV).
3. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 2005, 57:1377-1384.
4. Arnsten A.F., Scahill L., Findling R.L. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J. Child. Adolesc. Psychopharmacol. 2007, 17:393-406.
5. Biederman J., Melmed R.D., Patel A., McBurnett K., Donahue J., Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008, 13:1047-1055.
6. Biederman J., Melmed R.D., Patel A., McBurnett K., Konow J., Lyne A., Scherer N. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121:e73-e84.
7. Biederman J., Melmed R.D., Patel A., McBurnett K., Konow J., Lyne A., Scherer N. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121:e73-e84.
8. Buzsaki G., Kennedy B., Solt V.B., Ziegler M. Noradrenergic control of thalamic oscillation: the role of alpha-2 receptors. Eur. J. Neurosci. 1991, 3:222-229.
9. Chalmers I., Bracken M.B., Djulbegovic B., Garattini S., Grant J., Gulmezoglu A.M., Howells D.W., Ioannidis J.P., Oliver S. How to increase value and reduce waste when research priorities are set. Lancet 2014, 383:156-165.
10. Cheng J.Y., Chen R.Y., Ko J.S., Ng E.M. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194:197-209.
11. Clavenna A., Pandolfini C., Bonati M. Public disclosure of clinical trials in children. Curr. Ther. Res. Clin. Exp. 2002, 63:707-716.
12. Connor D.F., Barkley R.A., Davis H.T. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin. Pediatr. (Phila) 2000, 39:15-25.
13. Connor D.F., Findling R.L., Kollins S.H., Sallee F., Lopez F.A., Lyne A., Tremblay G Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010, 24:755-768.
14. De Sarro G.B., Ascioti C., Froio F., Libri V., Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br. J. Pharmacol. 1987, 90:675-685.
15. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7:177-188.
16. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation 1998, Guilford Press, New York, NY.
17. European Commission2008. Ethical considerations for clinical trials on medicinal products with the paediatric population. (available at ). http://www.ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf.
18. Faraone S.V., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child. Adolesc. Psychiatry 2010, 19:353-364.
19. Faraone S.V., Glatt S.J. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. J. Atten. Disord. 2010, 13:532-538.
20. Faraone S.V., McBurnett K., Sallee F.R., Steeber J., Lopez F.A. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents. Clin. Ther. 2013, 35:1778-1793.
21. Fleiss J Statistical Methods for Rates and Proportions 1981, Wiley, New York, NY.
22. Franowicz J.S., Kessler L.E., Borja C.M., Kobilka B.K., Limbird L.E., Arnsten A.F. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 2002, 22:8771-8777.
23. Garattini S., Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009, 338:b1025.
24. Hanwella R., Senanayake M., V de S. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011, (11):176.
25. Hazell P.L., Stuart J.E. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J. Am. Acad. Child. Adolesc. Psychiatry 2003, 42:886-894.
26. Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The Cochrane Collaboration[U+05F3]s tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
27. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
28. Hirota T., Schwartz S., Correll C.U. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J. Am. Acad. Child. Adolesc. Psychiatry 2014, 53:153-173.
29. Horrigan J.P., Barnhill L.J. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J. Child. Adolesc. Psychopharmacol 1995, 5:215-223.
30. Hunt R.D., Arnsten A.F., Asbell M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 1995, 34:50-54.
31. Hunt R.D., Capper L., O'Connell P. Clonidine in child and adolescent psychiatry. J. Child. Adolesc. Psychopharmacol. 1990, 1:87-102.
32. Hunt R.D., Minderaa R.B., Cohen D.J. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J. Am. Acad. Child. Psychiatry 1985, 24:617-629.
33. Kollins S.H., Lopez F.A., Vince B.D., Turnbow J.M., Farrand K., Lyne A., Wigal S.B., Roth T. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 2011, 21:111-120.
34. Kugler J., Seus R., Krauskopf R., Brecht H.M., Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br. J. Clin. Pharmacol. 1980, 10(Suppl 1):71S-80S.
35. Lara C., Fayyad J., de G.R., Kessler R.C., Aguilar-Gaxiola S., Angermeyer M., Demytteneare K., de G.G., Haro J.M., Jin R., Karam E.G., Lepine J.P., Mora M.E, Ormel J., Posada-Villa J., Sampson N. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol. Psychiatry 2009, 65:46-54.
36. National Collaborating Centre For Mental Health, 2008. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE, London.
37. Newcorn J.H., Kratochvil C.J., Allen A.J., Casat C.D., Ruff D.D., Moore R.J., Michelson D. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am. J. Psychiatry 2008, 165:721-730.
38. Newcorn J.H., Schulz K., Harrison M., DeBellis M.D., Udarbe J.K., Halperin J.M. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr. Clin. North Am. 1998, 45. (1099-22, viii).
39. Newcorn J.H., Stein M.A., Childress A.C., Youcha S., White C., Enright G., Rubin J. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J. Am. Acad. Child. Adolesc. Psychiatry 2013, 52:921-930.
40. Palumbo D.R., Sallee F.R., Pelham W.E., Bukstein O.G., Daviss W.B., McDermott M.P Clonidine for attention-deficit/hyperactivity disorder: I. efficacy and tolerability outcomes. J. Am. Acad. Child. Adolesc. Psychiatry 2008, 47:180-188.
41. Pohl G.M., Van Brunt D.L., Ye W., Stoops W.W., Johnston J.A. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv. Res. 2009, 9:95.
42. Posey D.J., McDougle C.J. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev. 2007, 13:465-474.
43. Sallee F., Connor D.F., Newcorn J.H. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J. Child. Adolesc. Psychopharmacol. 2013, 23:308-319.
44. Sallee F.R. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad. Med. 2010, 122:78-87.
45. Sallee F.R., Kollins S.H., Wigal T.L. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 2012, 22:206-214.
46. Sallee F.R., Lyne A., Wigal T., McGough J.J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 2009, 19:215-226.
47. Sallee F.R., McGough J., Wigal T., Donahue J., Lyne A., Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J. Am. Acad. Child. Adolesc. Psychiatry 2009, 48:155-165.
48. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., Arnsten A.F., Cohen D.J., Leckman J.F. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. J. Psychiatry 2001, 158:1067-1074.
49. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., Arnsten A.F., Cohen D.J., Leckman J.F. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. J. Psychiatry 2001, 158:1067-1074.
50. Sikirica V., Findling R.L., Signorovitch J., Erder M.H., Dammerman R., Hodgkins P., Lu M., Xie J., Wu E.Q. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs 2013, 27:943-953.
51. Sikirica V., Haim E.M., Xie J., Macaulay D., Diener M., Hodgkins P., Wu E.Q. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics 2012, 30:e1-15.
52. Sorkin E.M., Heel R.C. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986, 31:301-336.
53. Tourette's-Syndrome-Study-Group Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527-536.
54. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2008, 18:62-73.
55. van Zwieten P.A., Chalmers J.P. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther. 1994, 8:787-799.
56. Wang M., Ramos B.P., Paspalas C.D., Shu Y., Simen A., Duque A., Vijayraghavan S., Brennan A., Dudley A., Nou E., Mazer J.A., McCormick D.A., Arnsten A.F. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129:397-410.
57. Wilens T.E., Bukstein O., Brams M., Cutler A.J., Childress A., Rugino T., Lyne A., Grannis K., Youcha S. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 2012, 51:74-85.
58. Yamadera H., Ferber G., Matejcek M., Pokorny R. Electroencephalographic and psychometric assessment of the CNS effects of single doses of guanfacine hydrochloride (Estulic) and clonidine (Catapres). Neuropsychobiology 1985, 14:97-107.